C.R. Bard has entered into a definitive agreement to buy Medafor, a developer and supplier of plant based hemostatic agents, in a $200m deal. The company also agreed to future contingent payments up to an additional $80m, if Medafor ...
Tags: hemostatic agents, Medicine